Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era—Is it time for a new paradigm shift? A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era—Is it time for a new paradigm shift? A systematic review and meta-analysis

Published:2023-07 Issue: Volume:187 Page:77-86
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Peters Inge T.A.,Marchetti Claudia^ORCID,De Palma Antonella,Giannarelli Diana^ORCID,Carcagnì Antonella,Scambia Giovanni,Fagotti Anna

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer;Vergote;New Engl J Med,2010

2. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial;Kehoe;Lancet,2015

3. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850);Fagotti;Int J Gynecol Cancer,2020

4. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials;Du Bois;Cancer,2009

5. Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer;Jiang;Gynecol Oncol,2021

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. La chirurgie du cancer épithélial avancé de l’ovaire : escalade et désescalade;Bulletin de l'Académie Nationale de Médecine;2024-07

2. How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature;Frontiers in Oncology;2024-03-08

3. New windows of surgical opportunity for gynecological cancers in the era of targeted therapies;International Journal of Gynecologic Cancer;2024-03

4. Primary vs. interval cytoreduction for high-grade serous ovarian cancer: oncological outcomes from a retrospective study at a single tertiary referral center;European Journal of Gynaecological Oncology;2024

5. Clinical characteristics and status of treatment of small-cell carcinoma of the ovary, hypercalcemic type in the Chinese population: a meta-analysis;Journal of Gynecologic Oncology;2024